Journal article
Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies
Abstract
Cytokine antagonists are monoclonal antibodies that offer new treatment options for refractory asthma but will also increase complexity because they are effective only for patients with certain asthma subtypes that remain to be more clearly defined. The clinical and inflammatory heterogeneity within refractory asthma makes it difficult to manage the disease and to determine which, if any, biologic therapy is suitable for a specific patient. The …
Authors
Katial RK; Bensch GW; Busse WW; Chipps BE; Denson JL; Gerber AN; Jacobs JS; Kraft M; Martin RJ; Nair P
Journal
The Journal of Allergy and Clinical Immunology In Practice, Vol. 5, No. 2, pp. s1–s14
Publisher
Elsevier
Publication Date
3 2017
DOI
10.1016/j.jaip.2016.11.029
ISSN
2213-2198